Kras Wild-Type Tumor

CHICAGO — Potentially targetable oncogenic rearrangements are more prevalent among patients with KRAS wild-type pancreatic cancer than those with KRAS-mutated disease, according to study results presented at ASCO Annual Meeting.

CHICAGO — The addition of nimotuzumab to gemcitabine prolonged OS and PFS among patients with KRAS wild-type locally advanced or metastatic pancreatic cancer, according to randomized phase 3 study results presented at ASCO Annual Meeting.